Ex-Surgeon General Pushes FDA 'Third Way' on Peptides
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Jerome M. Adams, the 20th US surgeon general, argues in an opinion piece that the FDA should adopt a 'third way' on peptides — neither blanket crackdown nor unrestricted access — as Americans increasingly buy them from unregulated online sellers without medical supervision.
- The FDA's Pharmacy Compounding Advisory Committee meets July 23-24 to consider restoring certain peptides to the list of substances eligible for compounding by licensed 503A pharmacies, with a follow-up meeting scheduled before February 2027.
- Kyle Diamantas, the FDA's acting commissioner, has a 'timely opportunity' to approve a structured, clinician-guided framework making selected, widely used peptides available under strict quality, sourcing, and sterility oversight.
- Under Adams' proposed framework, patients would access peptides only through licensed clinicians who evaluate individual needs and risks, provide balanced information from studies and real-world use, and ensure ongoing outcome monitoring and reporting.
- Compounded peptides under this framework would carry explicit disclaimers and require documented informed-consent decisions, without replacing full FDA approval pathways or suggesting compounded versions equal rigorously tested manufactured drugs.
- The piece notes that peptides are not monolithic: insulin and GLP-1 agonists like semaglutide are FDA-approved and transformative, while wellness-marketed gray-zone peptides carry no equivalent evidence or quality assurance.
- Structured oversight would generate real-world safety and efficacy data the compounds currently lack, turning the clinician-supervised channel into an evidence-gathering mechanism alongside patient protection.
Why it matters: The July 23-24 PCAC meeting is the first formal regulatory reconsideration of peptide compounding in years, and a framework recommendation would redirect the millions of Americans already self-dosing through online sellers toward quality-controlled, clinician-supervised products. Adoption would create a parallel evidence pipeline for compounds that currently have neither approval data nor quality assurance, while a denial would likely deepen the unregulated market the FDA aims to reduce.
